Walsh Angela 4

What Happened

• Angela Walsh, Chief Financial Officer of Dogwood Therapeutics (DWTX), was granted a derivative award on March 5, 2026: options covering 82,500 shares. The Form 4 reports the acquisition as a grant/award (code A) with a reported price of $0.00; the filing lists this as a derivative security (stock option), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-05; Form 4 filed: 2026-03-06 (timely).
• Transaction type/code: Grant/Award of derivative security (A).
• Quantity: 82,500 option shares; reported price: $0.00 (reported value $0 on Form 4).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnote: The option vests one-third on March 5, 2027 and then 1/24th monthly thereafter.
• No indication of a 10b5-1 plan, cashless exercise, or tax-withholding sale in the filing excerpt.

Context

• This was a time‑based option grant as part of compensation; the options vest over time and were not sold immediately. Such awards are common executive compensation and do not by themselves indicate insider buying or selling intent.